NanoAlchemie Files Patent on Groundbreaking Drug Delivery System for Psychedelics and Medicinal Mush
Updated: Nov 16, 2021
Los Angeles – TheNewswire - November 11, 2021 NanoAlchemie, a drug delivery research company, is pleased to announce its patent application for a novel drug delivery system for psychedelic drugs, psilocybin, entheogens, and beneficial medical mushroom extracts, has been accepted by the US Patent Office. Entheogens are psychoactive substances that alter perception and mood, often used for spiritual development or treatment of certain psychological conditions, such as Peyote or Ayahuasca.
The non-provisional patent filing claims priority from the US Provisional Patent Application #63/109,912, filed on Nov. 5, 2020.
The patent was filed by NanoAlchemie Founder and President Dr. Richard Kaufman, who previously developed and patented a unique nanoparticle drug delivery system that was assigned to NanoSphere Health Sciences to produce NanoCannabis, the first patent-protected product brand alternative to vaping, smoking, and ingesting cannabis.
The current invention is a more advanced form of nanotechnology that creates stable, safe nano-dimensional structures that can be used to rapidly and precisely deliver psychedelic drugs, psilocybin, and medicinal mushroom extracts through the skin, through the gums in the mouth, through the gastrointestinal tract, and rapidly to the brain through the olfactory and trigeminal nerves in the nasal cavity.
“Psilocybin and other psychedelic drugs hold great promise for a variety of crippling medical and psychological conditions, but true advancements in psychedelic therapy require consistent pharmacokinetic profiles, and effective, safe, and precise dosage delivery,” explains Dr. Kaufman. “The NanoAlchemie Delivery System is, in my opinion, the first drug delivery solution designed for precise, fast delivery of psilocybin, entheogens, and psychedelic drug treatments.”
Kaufman says the potential for the use of psychedelic drugs and entheogens in traditional medicine is being hampered by a combination of poor pharmacokinetics, imprecise dosage, slow onset of the medical effects, and unpredictable results. What NanoAlchemie has done is to create a nano-drug delivery system that offers fast-acting, precise dosage of these types of drugs to provide safer and more predictable effects for the patient.
As one example of the problem, many psychedelic drugs, entheogens, and medicinal mushroom extract compounds demonstrate poor absorption and hence poor bioavailability, as well as difficulty in passing the Blood to Brain Barrier (BBB).
As well, when psilocybin mushrooms are ingested orally, it is not the psilocybin itself that is effective in treating mental issues like depression or anxiety. Rather, the prodrug psilocybin is transformed into the active drug psilocin as it passes through the liver. In this process, an unpredictable amount of the psilocin is destroyed, making it difficult to provide a truly precise dosage.
As part of NanoAlchemie’s invention, psilocybin is efficiently converted to psilocin through a process known as phosphorylation and manufactured into nanostructures that can rapidly be absorbed directly through mucous membranes in the nose and gums, or even through the skin, and avoid liver metabolism. The result is a medication that provides more predictable results with a much faster onset.
Testing of typical psilocybin treatments, for example, showed the onset of effects from ingesting psilocybin orally is typically reported to begin after 30 minutes. By contrast, the average onset time of NanoAlchemie’s IntraNasal NanoPsilocin formula is only 11 minutes. It was also found that the average onset time of IntraNasal Nano-5-Meo-DMT was 5.25 minutes, a remarkable achievement due to this advancement in nanotechnology.
The problem is even more pronounced with medicinal mushrooms such as Lion’s Mane, Turkey Tail, Chaga, or Reishi mushrooms, among others. While the medicinal benefits of compounds in these mushrooms have been demonstrated in various studies, Kaufman explains that those benefits do not typically occur in the patient.
The primary reason is that medicinal mushrooms contain immune-supporting ß-glucan polysaccharides embedded in their cell walls, made from an indigestible, unabsorbable fibrous material called "chitin". Consequentially ß-glucan has less than 5% bioavailability. A therapeutic amount of a medicinal mushroom extract requires ingesting a multi-gram dose, which would be both impractical and very expensive.
However, NanoAlchemie has developed an innovative process to deliver medicinal mushroom extracts that massively increases the bioavailability of their valuable medicinal phytochemicals. By nanomilling medicinal mushrooms, grinding them down to nanosizes, and self-emulsifying them in the intestinal tract, the delivery system exponentially increases absorption and bioavailability for therapy.
“Simply put, these types of medicinal mushrooms have never reached their potential because they are so difficult to absorb for mammals of all types, including humans,” explains Dr. Kaufman. “This is a problem we have solved, creating a huge new market for medicinal mushroom compounds that can be used for boosting the immune system, improving cognition, or even helping in the treatment of cancer.”
The company is currently creating nano-structured formulations of various medically appropriate drugs that can be used in a variety of treatments, and particularly for psychedelic drugs that treat depression, anxiety, and addiction. The company plans to license its new technology to appropriate drug companies working in the field of psychedelic and holistic medicine.
For more information or to schedule an interview, please e-mail email@example.com or call Dr. Richard Kaufman at (310) 990-6770.
Forward Looking Statement Caution This news release includes forward looking statements that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs regarding the future. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements, whether as a result of new information, future events or otherwise.